Fig. 1: AdipoRon clears phosphorylated tau and NFT via AMPK and GSK3b.
From: Reversal of neuronal tau pathology via adiponectin receptor activation
A Immunofluorescence of phosphorylated Tau (pTau) at S202/T205 and NFT (MC-1 antibody) in Tau neurons following 24-h treatment with 10 μM AdipoRon ± 8 μM AMPK inhibitor Compound C (pTau: n = 6 mice, n = 43–58 neurons per treatment; NFT: n = 8 mice, n = 53–79 neurons per treatment), quantification of immunofluorescence images above; one-way ANOVA with Tukey’s multiple comparison’s test, scale bar 15 μm. B Immunofluorescence detection and quantification of phosphorylated AMPK and total AMPK in individual Tau neurons following 10-min treatment with 10 μM AdipoRon (pAMPK: n = 5 mice, n = 57–63 neurons per treatment; total AMPK: n = 3 mice, n = 44–56 neurons per treatment); Student’s t-test with Welch’s correction. C Immunofluorescence detection and quantification of phosphorylated GSK3b and total GSK3b in Tau neurons following 10-min treatment with 10 μM AdipoRon (pGSK3b: n = 5 mice, n = 42–47 neurons per treatment; total GSK3b: n = 5 mice, n = 37–55 neurons per treatment), Student’s t-test with Welch’s correction. D Immunofluorescence detection of pTau after 24-h treatment with 15 mM LiCl (n = 6 mice; n = 40–43 neurons per treatment). Data shown as mean ± SEM *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
